Healthcare Industry News: iMediSync
News Release - September 23, 2022
iSyncWave EEG Scanner Receives FDA 510k ClearanceSEOUL, South Korea, Sept. 23, 2022 -- (Healthcare Sales & Marketing Network) -- iMediSync announced that iSyncWave, the company's medical device EEG scanner, has been granted 510k clearance from the US Food and Drug Administration (FDA) on August 10th.
This device was recently registered as an innovative prototype product by the Public Procurement Service in South Korea and was introduced to the mobile medical checkup service at Pusan National University Hospital. Data is continuously collected from patients with various diseases and illnesses (stroke, Parkinson's, etc.) at leading university hospitals in South Korea, such as Seoul National University Hospital and Asan Medical Center.
In September, iSyncWave will be presented at the University of Oxford EEG seminar for children with developmental disabilities.
Following the FDA 510k clearance, iMediSync plans to increase and expand overseas sales.
Seungwan Kang, the CEO of iMediSync stated, "After CES 2022 and AAIC (Alzheimer's Association International Conference), we are receiving many inquiries from the US, Europe, Australia, and other countries, particularly around research and clinical introduction from leading universities and institutions around the world. With FDA 510k clearance, we can provide product information and conduct collaborative research to sell iSyncWave. We are also preparing the CE (EU), TGA (Australia) and PMDA (Japan) registrations for countries that require registration other than from the FDA for import."
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.